Literature DB >> 20826407

Immune modulators as therapeutic agents for cutaneous T-cell lymphoma.

Alain H Rook1, Bernice Benoit, Ellen J Kim, Carmela C Vittorio, Aleksandra Anshelevich, Brian A Raphael, Camille E Introcaso, Jennifer M Gardner, Katherine G Evans, Kelly Morrissey, Sara Samimi, Amy C Musiek, Louise C Showe, Mariusz A Wasik, Maria Wysocka.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20826407      PMCID： PMC3877673          DOI： 10.3816/CLML.2010.s.017

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN： 2152-2669


× No keyword cloud information.
  18 in total

1.  The addition of interferon gamma to oral bexarotene therapy with photopheresis for Sézary syndrome.

Authors:  Karen S McGinnis; Ravi Ubriani; Sarah Newton; Jacqueline M Junkins-Hopkins; Carmela C Vittorio; Ellen J Kim; Maria Wysocka; Alain H Rook
Journal:  Arch Dermatol       Date:  2005-09

2.  A role for regulatory T cells in cutaneous T-Cell lymphoma; induction of a CD4 + CD25 + Foxp3+ T-cell phenotype associated with HTLV-1 infection.

Authors:  Patrick T Walsh; Bernice M Benoit; Maria Wysocka; Nicole M Dalton; Laurence A Turka; Alain H Rook
Journal:  J Invest Dermatol       Date:  2006-03       Impact factor: 8.551

3.  High clinical response rate with multimodality immunomodulatory therapy for Sézary syndrome.

Authors:  Stephen K Richardson; Julie H Lin; Carmela C Vittorio; Ellen J Kim; Jessica S Yoon; Jacqueline Junkins-Hopkins; Alain H Rook
Journal:  Clin Lymphoma Myeloma       Date:  2006-11

4.  Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma.

Authors:  E H Kaplan; S T Rosen; D B Norris; H H Roenigk; S R Saks; P A Bunn
Journal:  J Natl Cancer Inst       Date:  1990-02-07       Impact factor: 13.506

5.  A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides.

Authors:  Madeleine Duvic; Matthew L Sherman; Gary S Wood; Timothy M Kuzel; Elise Olsen; Francine Foss; Robert J Laliberté; John L Ryan; Kristilyn Zonno; Alain H Rook
Journal:  J Am Acad Dermatol       Date:  2006-09-08       Impact factor: 11.527

Review 6.  Immunopathogenesis and therapy of cutaneous T cell lymphoma.

Authors:  Ellen J Kim; Stephen Hess; Stephen K Richardson; Sara Newton; Louise C Showe; Bernice M Benoit; Ravi Ubriani; Carmela C Vittorio; Jacqueline M Junkins-Hopkins; Maria Wysocka; Alain H Rook
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

7.  Biological effects of bexarotene in cutaneous T-cell lymphoma.

Authors:  Jeanne B Budgin; Stephen K Richardson; Sarah B Newton; Maria Wysocka; Mohamed H Zaki; Bernice Benoit; Alain H Rook
Journal:  Arch Dermatol       Date:  2005-03

8.  Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses.

Authors:  A H Rook; G S Wood; E K Yoo; R Elenitsas; D M Kao; M L Sherman; W K Witmer; K A Rockwell; R B Shane; S R Lessin; E C Vonderheid
Journal:  Blood       Date:  1999-08-01       Impact factor: 22.113

9.  Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15.

Authors:  Maria Wysocka; Bernice M Benoit; Sarah Newton; Livio Azzoni; Luis J Montaner; Alain H Rook
Journal:  Blood       Date:  2004-08-24       Impact factor: 22.113

10.  Bexarotene blunts malignant T-cell chemotaxis in Sezary syndrome: reduction of chemokine receptor 4-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokine.

Authors:  Stephen K Richardson; Sarah B Newton; Tami L Bach; Jeanne B Budgin; Bernice M Benoit; Julie H Lin; Jessica S Yoon; Maria Wysocka; Charles S Abrams; Alain H Rook
Journal:  Am J Hematol       Date:  2007-09       Impact factor: 10.047
View more
  1 in total

Review 1.  Systemic immunobiological, immunosuppressant, and oncologic agents for the treatment of dermatologic diseases during the SARS-CoV-2 (COVID-19) pandemic emergency: A quick review for a quick consultation.

Authors:  Giovanni Paolino; Santo Raffaele Mercuri; Pietro Bearzi; Carlo Mattozzi
Journal:  Dermatol Ther       Date:  2020-06-24       Impact factor: 3.858
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.